Next 10 |
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-03 08:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in t...
2024-05-28 09:44:27 ET Summary The stock of Tarsus Pharmaceuticals has doubled since it was first recommended in early September of last year. The initial rollout of XDEMVY has solidly exceeded expectations, and the company has also recently addressed its medium-term funding needs...
2024-05-13 07:00:04 ET Oren Livnat from H.C. Wainwright issued a price target of $61.00 for TARS on 2024-05-13 06:01:00. The adjusted price target was set to $61.00. At the time of the announcement, TARS was trading at $37. TARS currently trades -5.98% versus its 52 week...
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chie...
Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) traded at a new 52-week high today and are currently trading at $36.24. So far today, approximately 228.71k shares have been exchanged, as compared to an average 30-day volume of 451.13k shares. Tarsus Pharmaceuticals, Inc., a clinical-sta...
2024-05-08 21:45:35 ET Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Conference Call May 8, 2024 04:30 PM ET Company Participants David Nakasone - Head of Investor Relations Bobby Azamian - Chief Executive Officer and Chairman Aziz Mottiwala - Chief Commer...
2024-05-08 17:38:27 ET Gainers: CytomX Therapeutics ( CTMX ) +77% . Tarsus Pharmaceuticals ( TARS ) +15% . ZimVie ( ZIMV ) +13% . Equinix ( EQIX ) +11% . Consensus Cloud Solutions ( CCSI ) +10% . Losers: Cardl...
2024-05-08 17:08:37 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript Tarsus Pharmaceuticals Q1 2024 Earnings Preview Tarsus refinances ex...
News, Short Squeeze, Breakout and More Instantly...
Tarsus Pharmaceuticals Inc. Company Name:
TARS Stock Symbol:
NASDAQ Market:
Tarsus Pharmaceuticals Inc. Website:
2024-06-03 08:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in t...
2024-05-13 07:00:04 ET Oren Livnat from H.C. Wainwright issued a price target of $61.00 for TARS on 2024-05-13 06:01:00. The adjusted price target was set to $61.00. At the time of the announcement, TARS was trading at $37. TARS currently trades -5.98% versus its 52 week...